A drug's 'price' is two different numbers, and the gap can be enormous

When someone says what a drug "costs," they are almost always quoting one of two very different numbers. The list price is the public sticker the manufacturer sets. The net price is what the manufacturer actually keeps after the rebates and discounts it pays to insurers and their middlemen. The gap between them can be enormous — and which number a given person effectively pays depends entirely on how, and whether, they are insured.

Two prices for the same pill

Every brand-name drug has a list price, technically the wholesale acquisition cost, which the manufacturer chooses and publishes. But that is rarely the amount the manufacturer ends up with. To win a spot on an insurance plan's formulary, the manufacturer pays rebates back to the pharmacy benefit manager and insurer — often a large percentage of the list price. What is left after those rebates is the net price, the manufacturer's true realized revenue.

The two numbers can move in opposite directions at the same time, which is the single most counterintuitive fact in US drug pricing. A manufacturer can raise a drug's list price year after year while the net price it collects stays flat or falls, because the increases are being handed straight back as bigger rebates. The list price goes up; the money the maker keeps does not.

The insulin case, in hard numbers

The clearest documented example comes from insulin, which a bipartisan US Senate Finance Committee investigation dissected over nearly two years using more than 100,000 pages of internal manufacturer and pharmacy-benefit-manager documents [s1]. The committee's 2021 report laid the two prices side by side.

For the insulin Humalog, over one five-year period the list price rose 27% while the net price — what the manufacturer actually collected after rebates — fell 10% [s1]. For another manufacturer's insulins, list prices grew 140% over eight years while net prices dropped 41% [s1]. In other words, the drugs got cheaper for the manufacturer to sell even as their sticker prices soared. The report also documented that two manufacturers weighed cutting list prices by as much as 50% in 2018 and decided against it, because a lower list price would mean smaller rebates and a worse position on formularies [s1]. The incentive, perversely, ran toward a higher list price paired with a bigger rebate, not toward a lower price for anyone.

Why the gap decides what you pay

If the manufacturer nets far less than the list price, why does the gap matter to patients? Because not everyone pays the net price. The rebates flow to insurers and PBMs; they do not necessarily reach the patient at the counter. And a large group of people pays off the list price directly: the uninsured, who have no plan negotiating rebates on their behalf, and the insured who pay a percentage of the drug's price or are still inside a deductible, where cost-sharing is often calculated on the list price rather than the rebated net.

That is how the same drug can be cheap for the health system and ruinous for an individual. The plan and its middleman capture the rebate; the person paying list at the pharmacy captures none of it. The list-versus-net gap is not an accounting curiosity — it is precisely the mechanism that determines whether a drug is affordable for a particular person.

The gap is why "discounts" can mislead

Understanding the two prices also decodes a lot of drug-pricing news. When Medicare announced its first negotiated prices, the headline discounts of 38% to 79% were measured against 2023 list prices [s2]. But the program's estimated savings — about $6 billion, or roughly 22% — were measured against 2023 spending net of existing rebates [s2]. Both figures are real; they simply use different baselines. A huge discount off an inflated list price shrinks considerably once you measure it against the net price the program was already paying. Any drug-savings claim is only interpretable once you know which of the two prices it is discounting from — and reporting that omits the distinction can make a modest change look dramatic, or the reverse.

What the evidence supports

The claim that a drug has a single price is simply false for most brand-name drugs: the list price and the net price are distinct, and the documented gap can be vast, with list prices rising even as net prices fall [s1]. The claim that this is a harmless internal accounting matter is also false: because rebates accrue to insurers and PBMs rather than to patients, the people who pay off list — the uninsured and those under a deductible — bear the full weight of a number the manufacturer itself does not collect [s1]. The practical upshot is that "what does this drug cost" has no single answer, and the honest response to any drug-price figure is to ask which price it refers to and who actually pays it.